Ovarian cancer drug will cost HAs millions

Health authorities will have to find millions of pounds to fund cancer drugs after the National Institute for Clinical Excellence backed the use of paclitaxel to treat patients with ovarian cancer.

You need to be an HSJ subscriber to read more


Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to hsj.co.uk
  • The HSJ app

Enquire about multi-user access